OPRX vs. RMNI, ZFOX, DHX, STCN, MCHX, EGIO, EEX, RGP, ZH, and LQDT
Should you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include Rimini Street (RMNI), ZeroFox (ZFOX), DHI Group (DHX), Steel Connect (STCN), Marchex (MCHX), Edgio (EGIO), Emerald (EEX), Resources Connection (RGP), Zhihu (ZH), and Liquidity Services (LQDT). These companies are all part of the "business services, not elsewhere classified" industry.
Rimini Street (NASDAQ:RMNI) and OptimizeRx (NASDAQ:OPRX) are both small-cap computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.
Rimini Street currently has a consensus target price of $4.50, suggesting a potential upside of 92.72%. OptimizeRx has a consensus target price of $15.86, suggesting a potential upside of 46.69%. Given OptimizeRx's higher probable upside, equities analysts plainly believe Rimini Street is more favorable than OptimizeRx.
73.8% of Rimini Street shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 41.3% of Rimini Street shares are owned by company insiders. Comparatively, 4.4% of OptimizeRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Rimini Street has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
Rimini Street received 11 more outperform votes than OptimizeRx when rated by MarketBeat users. Likewise, 63.49% of users gave Rimini Street an outperform vote while only 62.83% of users gave OptimizeRx an outperform vote.
In the previous week, Rimini Street had 3 more articles in the media than OptimizeRx. MarketBeat recorded 8 mentions for Rimini Street and 5 mentions for OptimizeRx. Rimini Street's average media sentiment score of 0.53 beat OptimizeRx's score of -0.10 indicating that OptimizeRx is being referred to more favorably in the news media.
Rimini Street has a net margin of 5.02% compared to Rimini Street's net margin of -24.56%. Rimini Street's return on equity of -7.72% beat OptimizeRx's return on equity.
Rimini Street has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Rimini Street, indicating that it is currently the more affordable of the two stocks.
Summary
Rimini Street beats OptimizeRx on 12 of the 18 factors compared between the two stocks.
Get OptimizeRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptimizeRx Competitors List
Related Companies and Tools
